Safety and Efficacy of Tissue Plasminogen Activator (tPA) in Neonates and Infants
This study has been terminated.
(difficulty in recruiting subjects)
Sponsor:
University of Louisville
Collaborator:
Genentech
Information provided by (Responsible Party):
University of Louisville
ClinicalTrials.gov Identifier:
NCT00265005
First received: December 12, 2005
Last updated: September 27, 2011
Last verified: September 2011
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine if alteplase is effective in dissolving a clot in a catheter in a large vein (central venous line or PICC line) or artery in infants less than 6 months of age.
| Condition | Intervention | Phase |
|---|---|---|
|
Thrombosis |
Drug: alteplase |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Dose-Ranging, Safety And Efficacy Of Cathflo(TM) Activase(R) (Alteplase) For The Treatment Of Central Catheter Occlusion In Neonates And Infants; Phase I |
Resource links provided by NLM:
Further study details as provided by University of Louisville:
Primary Outcome Measures:
- Restoration of central access device patency following one, two or three instillations of t-PA. [ Time Frame: within 180 minutes of administering the study drug ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Restoration of patency following instillation of 1 mg/mL (i.e., first instillation) [ Time Frame: within 60 minutes from the first instillation of study drug ] [ Designated as safety issue: No ]
- Restoration of patency following instillation of 1 mg/mL (i.e., second instillation) [ Time Frame: within 60 minutes from the second instillation of study drug ] [ Designated as safety issue: No ]
- Restoration of patency following instillation of 2 mg/mL (i.e., third instillation) [ Time Frame: within 60 minutes from the third instillation of study drug ] [ Designated as safety issue: No ]
- The following safety outcome measure will be evaluated: • Major bleeding complications • Sepsis • Embolic events • All serious adverse events [ Time Frame: Within 14 days of study drug administration ] [ Designated as safety issue: Yes ]
| Enrollment: | 12 |
| Study Start Date: | June 2005 |
| Estimated Study Completion Date: | June 2012 |
| Primary Completion Date: | December 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: All
All subjects receive active drug up to a total of 3 doses
|
Drug: alteplase
Iv administration of 1 mg/ml up to two times and 2 mg/ml if needed.
Other Name: Cathflo Activase
|
Show Detailed Description Eligibility| Ages Eligible for Study: | 28 Weeks to 66 Weeks |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Ability to provide written informed consent by the parent or legal guardian and comply with study assessments for the full duration of the study
- Hospitalized premature neonates (28- < 34 weeks CGA), term neonates (34 weeks-< 40 weeks CGA) and infants (> = 40 weeks to 6 months CGA).
- Presence of central access device. All types of permanent and temporary catheters are eligible [e.g., central venous catheter (CVC), peripherally-inserted central catheter (PICC), umbilical arterial catheter (UAC), or umbilical venous catheter (UVC)] except hemodialysis catheters. The catheter must be properly inserted as evidenced by the ability to have used the catheter at least once for its intended purpose (i.e., to withdraw blood and/or infuse fluids)and documentation correct catheter placement radiographically within 48 hours of the catheter becoming non-patent.
- Partial or total occlusion of at least one lumen of the catheter
Exclusion Criteria:
- CGA > 66 weeks
- Incorrect catheter placement or evidence of mechanical occlusion
- Occlusion due to suspected drug precipitate
- Active internal bleeding, involving intracranial or retroperitoneal sites, or the gastrointestinal, genitourinary, or respiratory tracts
- Recent history (i.e., < 6 months) of intraventricular hemorrhage (IVH) or other active intracranial process that could predispose to intracranial bleeding
- Superficial or surface bleeding, observed mainly at vascular puncture and access sites (e.g., venous cutdowns, arterial punctures) or site of recent surgical intervention
Any of the following known or suspected hemorrhagic events within the preceding 7 days or any other significant bleeding risk:
- Gastrointestinal bleeding
- Intra-ocular surgery
Any of the following known events or suspected hemorrhagic events within the preceding 48 hours
- Major surgery (excluding central line placement)
- Organ biopsy
- Major trauma
- Puncture of a non-compressible vessel within the previous 48 hours
- Treatment with indomethacin within the previous 48 hours
- Received any fibrinolytic agent within 24 hours of enrollment
- Known risk for embolization, including history of left heart thrombus, mitral mitral stenosis with atrial fibrillation, acute pericarditis, and subacute bacterial endocarditis
- Known hypersensitivity to alteplase or any component in the formulation of CathfloTM Activase®
- Prior enrollment in the current study
- Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated or the patient has a known condition for which bleeding constitutes a significant hazard
- Participation in another simultaneous interventional medical investigation or trial
- Documented or suspected catheter infection
- Thrombocytopenia (i.e. platelet count < 20,000)
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00265005
Locations
| United States, Kentucky | |
| University of Louisville | |
| Louisville, Kentucky, United States, 40202 | |
Sponsors and Collaborators
University of Louisville
Genentech
Investigators
| Principal Investigator: | Janice E Sullivan, MD | University of Louisville |
More Information
Additional Information:
No publications provided
| Responsible Party: | University of Louisville |
| ClinicalTrials.gov Identifier: | NCT00265005 History of Changes |
| Other Study ID Numbers: | tPA 255-04 |
| Study First Received: | December 12, 2005 |
| Last Updated: | September 27, 2011 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by University of Louisville:
|
alteplase occluded central venous catheter occluded arterial catheter |
occluded PICC neonates infants |
Additional relevant MeSH terms:
|
Thrombosis Embolism and Thrombosis Vascular Diseases Cardiovascular Diseases Tissue Plasminogen Activator Fibrinolytic Agents |
Fibrin Modulating Agents Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Cardiovascular Agents Therapeutic Uses Hematologic Agents |
ClinicalTrials.gov processed this record on May 23, 2013